You pointed this out the other day with another chart and the stock did head north. The chart was similar and I took notice because I thought it was so clear the way you pointed it out.
If I was a chart guy I’d be looking at the left side of the chart and ask why the right side isn’t a mirror image. If you look up until 2020 it looks pretty symmetric right? So what happened?; ). I think plans changed to start looking at a bigger picture that was going to take more time to prepare for. Seems to be just after data lock and Flaskworks at the time that NWBO would have been given the data that the chart started shifting first sideways then down. Somebody seemed to understand that more time might be needed but the amount of time seemed uncertain so the drift then gradual down slope to the lowest and slowest uptrend which was rushed there by May 10th last year. Was tissue agnostic designation being discussed with regulators back in 2020-2021?; ). The correction back up should take the chart up to $11 and beyond fairly quickly because the delay for everyone to get on board very likely has not been in vain but in preparation. NWBO is talking like DCVax is for more than just brain tumors. Have regulators been saying the same thing?; ). Did regulators want the bigger boat because they could see where the demand would be coming from and didn’t want to get caught in the middle of a stampede?; ). I don’t think Dr. Linda Liau just skips town for no reason when something important is about to be shared. Best wishes.
Market Data 
Markets 
AI
